<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243434</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-MAR-101</org_study_id>
    <nct_id>NCT04243434</nct_id>
  </id_info>
  <brief_title>PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial &amp; 3 Vial Formulation Marqibo® in Hematological Malignant Patients</brief_title>
  <official_title>An Open-Label, Randomized, Pharmacokinetic Study of vinCRIStine Sulfate LIPOSOME Injection Ready-to-Use (VSLI-RTU) Formulation (1-Vial) and Marqibo® Formulation (3-Vials) in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acrotech Biopharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axis Clinicals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acrotech Biopharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, open-label, 2-way crossover, pharmacokinetic study in adult
      patients with hematological malignancies eligible to receive either cyclophosphamide,
      doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab-CHOP (R-CHOP) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A
      or B) in which the Marqibo formulation and the 1-vial VSLI-RTU formulation of vincristine are
      administered in a 2-way crossover design over 2 treatment cycles (21 days each):

        -  Cohort A: Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during
           Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.

        -  Cohort B: VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during
           Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.

      Both formulations of vincristine sulfate LIPOSOME injection will be administered via a 60
      (±10) minute IV infusion.

      Blood samples for PK evaluation will be drawn at the following time points: immediately
      before infusion, 0.5 hour after the start of the infusion, 0.5 hour after the end of infusion
      (EOI), and 3, 8, 15, 24, 48, 72, and 96 hours post-EOI.

      In addition to Marqibo or VSLI-RTU, all patients will receive standard doses (per
      institutional or regional guidelines) of cyclophosphamide, prednisone, and doxorubicin, (and
      rituximab if patient is on the R-CHOP regimen), on Day 1 and prednisone (or prednisolone if
      consistent with institutional or regional guidelines) on Days 2 to 5.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK analysis Area under the concentration time curve (AUC)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate the serum pharmacokinetics (PK) of the 1-vial VSLI-RTU formulation versus the current Marqibo 3-vial formulation for intravenous (IV) injection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Marqibo formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1, and VSLI-RTU formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VSLI-RTU formulation given at a dose of 2.25 mg/m2 with no dose cap during Cycle 1 and Marqibo formulation given at 2.25 mg/m2 with no dose cap during Cycle 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Liposome</intervention_name>
    <description>Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Marqibo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <description>CHOP to be administered on Day 1 on Cycle 1 &amp; 2 ( 21-day Cycle) &amp; prednisone administration on Days 2 to 5 on Cycle 1 &amp; 2 ( 21-day Cycle)</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>cyclophosphamide. doxorubicin, vincristine , and prednisone</other_name>
    <other_name>Adriamycin, (Oncovin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>R-CHOP to be administered on Day 1 on Cycle 1 &amp; 2 ( 21-day Cycle) &amp; prednisone administration on Days 2 to 5 on Cycle 1 &amp; 2 ( 21-day Cycle)</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>cyclophosphamide. doxorubicin, vincristine , prednisone + Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patient has a hematological malignancy and is eligible to receive CHOP or R-CHOP
             regimen.

          -  Patient must have adequate hematological, renal, and hepatic function as specified
             below within 30 days prior to the first dose of study treatment:

          -  Patient has a left ventricular ejection fraction ≥50% by multigated acquisition scan
             or echocardiogram within 30 days prior to the first dose of study treatment.

        Key Exclusion Criteria:

          -  Patient has severe neurologic disorders (Grade 3 and above) including peripheral motor
             and sensory, central and autonomic neuropathy.

          -  Patient has a history of persistent active neurologic disorders including the
             demyelinating form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders,
             and other demyelinating conditions.

          -  Patient has used any investigational drugs, biologics, or devices within 30 days prior
             to study treatment or plans to use any of these during the course of the study.

          -  Patient has bowel obstruction, paralytic ileus, or uncontrolled chronic constipation.

          -  Patient has severe, active and uncontrolled hepatic disease or dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wasim Khan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acrotech Biopharma LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Brugard, CTM, MSW</last_name>
    <phone>218.284.9863</phone>
    <email>m.burgard@axisclinicals.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematology</keyword>
  <keyword>Hematological Malignancy</keyword>
  <keyword>CHOP</keyword>
  <keyword>R-CHOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

